A trial investigating the link between muscle loss and the severity of chemo side effects in secondary breast cancer
Research area: Secondary breast cancer
Research area: Secondary breast cancer
Professor Ellen Copson wants to find out if a person’s body composition and muscle mass influences the severity of the side effects they get following chemotherapy for secondary breast cancer. She’s carrying out a clinical trial across multiple parts of the UK.
Breast cancer that has spread to other parts of the body is called secondary (or metastatic) breast cancer. Although it’s currently incurable, it’s commonly treated with chemotherapy and this treatment can come with difficult side effects. So, we need to better understand why some women will experience more side effects than others and find ways to reduce them.
Professor Ellen Copson of the University of Southampton and her colleagues are conducting a trial to investigate whether the amounts of muscle mass and body fat people with secondary breast cancer have influences the side effects they experience from chemotherapy.
They’ll measure the body composition and arm muscle strength of 250 women with secondary breast cancer from 8 hospitals before they start their chemotherapy treatment. The study team will also ask questions about their mental and physical wellbeing. Then they’ll take these measurements again 3 and 6 months later.
Ellen’s team will be comparing these measurements with the side effects that the women report. This will allow them to better understand whether a person’s body composition impacts the amount and severity of side effects they experience from chemotherapy. It will also help them understand whether people’s muscle mass and body fat levels change during treatment for secondary breast cancer.
This project will allow us to better understand how a person’s body composition affects how severe their side effects from chemotherapy will be. This could help us to better identify women who have a higher risk of severe side effects. It could also lead to future studies looking at whether the dose of chemotherapy can be changed to match someone’s body composition and whether this can improve outcomes.
Over 61,000 people are living with secondary breast cancer in the UK. The majority of them will receive chemotherapy at some point during their treatment. And this research has the potential to improve quality of life for all of them.
Make a donation today to support groundbreaking breast cancer research like this.